# APT Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apt-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Burlingame, US
- Website: www.aptbio.com
- Total disclosed funding: $60M
- Latest round: Series B (Sep 30, 2008)
- Investors on record: 8

## About

APT Pharmaceuticals is a biotechnology firm focused on providing premium domain names and associated branding services tailored for the life sciences sector, facilitating brand visibility and recognition for its clients.Founded in 1999 and headquartered in Burlingame, California, APT Pharmaceuticals specializes in premium domain names and branding services. The company has undergone a strategic development since its inception, focusing solely on serving the biotechnology and life sciences industries. APT Pharmaceuticals successfully raised USD 32 mn in Series B financing on September 30, 2008, led by Three Arch Partners, with contributions from investors including Charter Life Sciences and Great Point Partners. The total amount raised by the company stands at USD 32 mn.APT Pharmaceuticals specializes in the sale of premium domain names, focusing on high-value, brandable domains suitable for businesses in the biotechnology and life sciences sectors. The core product offering includes a diverse portfolio of domain names with modern extensions such as .ai, .io, and .xyz. Their services include trademark validation and filing, AI-powered naming and branding tools, as well as facilitating domain purchase and transfer processes, aiming to enhance brand visibility for biotechnology firms, tech startups, and entrepreneurs across North America, Europe, and Asia.APT Pharmaceuticals generates revenue through direct sales of premium domain names and associated services such as trademark assistance and branding consultation. Clients can purchase domain names outright or utilize payment plans. For example, the domain AptBio.com is offered for USD 3,695. Additional revenue sources include managed naming contests where businesses collaborate with branding experts to develop unique name ideas, further boosting their brand identity.APT Pharmaceuticals aims to leverage the recent Series B funding of USD 32 mn to strengthen its product offerings and expand its geographical reach. The company is currently designing new domain name options tailored for the evolving biotechnology sector and plans to target emerging markets in Asia and Europe by the end of 2023. The funding will support these initiatives by enhancing branding services and expanding their portfolio of premium domains.

## Funding rounds

- Series B, Sep 30, 2008, $32M — InterWest Partners, Versant Ventures, Charter Life Sciences, Three Arch Partners, Pinnacle Ventures, Vivo Capital, Great Point Partners
- Series B, Sep 24, 2007, $22M — Versant Ventures, Charter Life Sciences, Vivo Capital, Great Point Partners
- Series A, Jul 21, 2005, $6M — Charter Life Sciences, Research Corporation Technologies

## Investors

- Charter Life Sciences (https://capitalatlas.ai/funds/charter-life-sciences) — Series A, Series B
- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Great Point Partners (https://capitalatlas.ai/funds/great-point-partners) — Series B
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series B
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series B
- Pinnacle Ventures (https://capitalatlas.ai/funds/pinnacle-ventures) — Series B